• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Examining Glucagon-Like Peptide-1 Receptor (Glp-1r) Agonists for Central Nervous System Disorders: Proceedings of a Workshop

Examining Glucagon-Like Peptide-1 Receptor (Glp-1r) Agonists for Central Nervous System Disorders: Proceedings of a Workshop

Paperback

Medical Reference

Currently unavailable to order

ISBN10: 030973505X
ISBN13: 9780309735056
Publisher: National Academies Press
Published: Nov 27 2025
Pages: 118
Weight: 0.40
Height: 0.40 Width: 5.99 Depth: 8.91
Language: English

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have recently received a lot of national attention. Repurposing GLP-1R agonists to treat some central nervous disorders is promising, but comparatively understudied. At a September 2024 workshop, the National Academies Forum on Neuroscience and Nervous System Disorders reviewed the current knowledge and research gaps about the mechanisms of action of GLP-1R agonists in the brain, and the evidence of their clinical efficacy for eating disorders, neurodegenerative diseases, substance use disorders, and pain.

Also from

National Academies of Sciences Engineering and Medicine

Also in

Medical Reference